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Abstract
Background: Limited studies have examined the association between lung cancer and bronchiectasis (BE). This
study evaluated the regional association between BE and lung cancer by analyzing the lobar location of lung
cancer in patients with underlying BE.
Methods: This clustered multi-level study enrolled patients who had underlying BE and were newly diagnosed
with lung cancer between January 1, 2010 and May 30, 2013 in two referral hospitals in South Korea. By analyzing
the presence of lung cancer and underlying BE as event variables at the level of lung lobes on chest computed
tomography (CT), we evaluated the association of BE and lung cancer by the locations of the diseases.
Results: Eighty-one patients with BE and combined lung cancer were enrolled. Within 486 lung lobes of the
patients, combined BE and lung cancer in the same lobe was found in 11 lobes (2.3 %). Using the general
estimating equation assuming BE as a risk factor of lung cancer, the results indicated that the prevalence of lung
cancer was significantly lower in the lobes with pre-existing BE (β = −1.09, p-value = 0.001).
Conclusions: Regionally, pre-existing BE was associated with a lower risk of the occurrence of lung cancer in the
same lobe.
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Background
Chronic inflammation plays a key role in carcinogenesis
via disordered necrotic cell death, subsequent epithelial
proliferation, and suppressed immunity [1]. Like other or-
gans, chronic inflammation in the lung, such as chronic
obstructive pulmonary disease (COPD), is associated with
an increased risk of lung cancer, mainly related to re-
peated airway epithelial injury and accompanied high cell
turnover rates [2–4].
Bronchiectasis (BE) is a representative chronic inflam-
matory airway disease characterized by abnormal and
permanent dilatation of the bronchi, accompanied by
high levels of inflammatory cytokines [5]. Unlike COPD,
however, the impact of the inflammation accompanying
BE on lung cancer remains unclear.
Considering reports on the influence of inflammatory
signaling in carcinogenesis, chronic inflammation caused
by BE might be associated with an increased risk of lung
cancer because of the local effects of chronic inflamma-
tion caused by repeated airway injury and impaired
mucociliary clearance. If this postulate holds, it is rea-
sonable to think that the incidence or prevalence of can-
cer should be increased close to the pre-existing BE in
location [3, 6, 7].
However, there are only limited data on an
association between BE and the risk of lung cancer.
A few studies reported that patients with BE had el-
evated levels of serum transforming growth factor-β1
(TGF-β1), which is a potential protective factor
against carcinogenesis [5, 8, 9]. In patients with cys-
tic fibrosis showing radiological features of BE, the
cystic fibrosis gene mutation was inversely associated
with some malignancies [10]. This supports the hy-
pothesis that the association between BE and lung
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cancer is different from the previously reported role
of inflammation in lung cancer carcinogenesis.
The aim of this study was to assess the association be-
tween BE and the risk of lung cancer by analyzing the lobar
location of lung cancer in patients with underlying BE.
Methods
Study design and subjects
We designed this multi-center-based, retrospective, clus-
tered, multi-level study analyzing the presence of lung
cancer and BE as event variables at the level of lung
lobes in patients with underlying chronic BE who were
newly diagnosed with lung cancer between January 1,
2010 and May 30, 2013. We identified the patients older
than 40 years with BE at two referral hospitals in South
Korea: Seoul National University Boramae Medical Cen-
ter and Seoul National University Hospital. Among
them, the patients newly diagnosed with lung cancer in
the study period were enrolled and analyzed. The flow
diagram selecting study population for analyses is shown
in Fig. 1. The design of this study was approved by the
Institutional Review Board of Seoul National University
Hospital (IRB No. H-1312-123-547) and Seoul National
University Boramae Hospital (IRB No. 16-2014-137). The
institutional review boards waived the need for written in-
formed consent from the participants. Patient records
were anonymized and de-identified prior to analysis.
Pre-existing BE was assessed and confirmed with chest
computed tomography (CT) analyzed independently by
a radiologist and a pulmonologist [11]. If inconsistent
findings were found, a consensus decision was reached
following a discussion. Patients were excluded if they
had BE secondary to mechanical effects caused by lung
cancer. Evaluation of secondary BE was based on com-
parison with previous CTs if available, and inspection of
traction and bronchodilation caused by lung cancer
(Additional file 1: Figure S1). Reviewing the chest CT
findings, the locations of the previous BE and newly devel-
oped lung cancer were analyzed among lobes (the lingula
of the left lung was considered a distinct lobe, giving six
lobes per patient). Demographic data were collected from
each patient, including smoking history, baseline spiro-
metric measurements, severity index of BE calculated
using the modified Bhalla system and the Reiff score, pres-
ence and severity of combined emphysema, tissue type
and staging of the diagnosed lung cancer [12, 13].
Among the patients with combined emphysema, the
severity of emphysema was assessed visually with CT
images according to the modified Goddard scoring sys-
tem [14, 15]. Six images of three lung slices were evalu-
ated for each patient (the right and left lungs evaluated
separately). Each image was classified as normal (score
0), ≤ 5 % affected (score 0.5), ≤25 % affected (score 1), ≤
50 % affected (score 2), ≤75 % affected (score 3) or
>75 % affected (score 4). The average score of six images
was considered as a representative value of the severity of
emphysema in each patient, and the patients were further
categorized into three groups as previously suggested [16]:
no/mild emphysema (average severity score < 1); moderate
emphysema (1 ≤ average severity score < 2.5); and severe
emphysema (average severity score ≥ 2.5).
Data analysis
Age was given as the median and interquartile range
(IQR), while other continuous variables were given as
the means with the standard deviations. To evaluate cor-
relations within a subject and within lobes by repeated
measures of the events (BE and lung cancer), generalized
estimating equations were used and the β-value was cal-
culated. To eliminate any possible interaction that might
Fig. 1 A Flow Diagram of the Study Population
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exist between smoking and BE, analyses were further
stratified by the smoking status of the patients. In
addition, since emphysema is an important risk factor
for lung cancer, subgroup analyses were performed in
groups classified according to the presence and severity
grade of emphysema. P-values < 0.05 were recognized as
indicative of statistical significance. All analyses were
performed using the SPSS software, version 19.0 (SPSS
Inc., Chicago, IL, USA).
Results
Baseline characteristics of the study population
Eighty-one patients with pre-existing BE were diagnosed
with lung cancer during the study period. The baseline
characteristics of the study participants are shown in
Table 1. The median age of the study population was 70
(IQR 61–76) years and 52 (64.2 %) were male. Forty-four
patients (54.4 %) had a history of exposure to smoking,
and 53 (65.4 %) had no or mild emphysema in CT. The
baseline spirometric results of the patients at the time of
diagnosis with lung cancer included a mean FEV1/FVC ra-
tio of 67.7 and mean predicted FEV1 of 87.9 %.
Characteristics of diagnosed lung cancer
Seventy-three patients (90.1 %) were diagnosed with non-
small-cell lung cancer. Adenocarcinoma was the most
common histological type (51.9 %), followed by squamous
cell carcinoma (22.2 %) and poorly differentiated
carcinoma (7.4 %). When stratified by smoking status,
there was significant difference in the histologic type of
lung cancer between the current/former smoker group
and the never-smoker group (Table 2). The proportion of
squamous cell carcinoma and small-cell lung cancer was
higher in the current/former smoker group, whereas the
proportion of adenocarcinoma was higher in the never-
smoker group.
Thirty patients with non-small cell lung cancer had
stage I cancer at the time of diagnosis. Of the eight
small-cell lung cancer patients, four were at a limited
stage when diagnosed. There was no significant differ-
ence in the stage of lung cancer at the time of diagnosis
according to the smoking status.
Regional association between bronchiectasis and lung
cancer
To assess the locations of BE and lung cancer, we evalu-
ated 486 lung lobes from 81 patients. Because 4 patients
had primary tumors in 2 lobes, the total number of lobes
affected with lung cancer was 85. Lung cancer most
commonly involved the right upper lobe (5.6 %),
followed by the right lower (4.1 %) and left upper lobe
(3.9 %) (Table 3). The mean number of lobes affected
with BE per patient was 1.7. The mean severity index of
BE was 8.0 assessed with the modified Bhalla system and
4.4 assessed with the Reiff score, respectively [12, 13].
BE most commonly involved the left lower lobe (7.4 %),
followed by the right upper (5.6 %), right lower (5.6 %),
and left upper (4.7 %) lobes. Eleven (2.3 %) lobes con-
tained both BE and lung cancer. There were 123
(25.3 %) lobes with BE only and 74 (15.2 %) with lung
cancer only. When using the general estimating equation
assuming BE as a risk factor of lung cancer, the calculated
β-value was −1.091 (p = 0.001) in the analysis of the total
lung cancer patients, indicating that the prevalence of lung
cancer was significantly lower in lobes with pre-existing
BE (Table 4). When analyzing lobes from lung cancer pa-
tients separately by smoking status, prevalence of lung
cancer remained significantly lower in lobes with pre-
existing BE in both the current/former smoker group (β =
−1.012, p = 0.021) and the never-smoker group (β =
−1.152, p = 0.011). When evaluating the lobes stratified by
the presence and severity of emphysema of the patients,
prevalence of lung cancer was significantly lower in lobes
with pre-existing BE in patients with no or mild emphy-
sema (β = −1.244, p = 0.003). Although not statistically sig-
nificant, similar trends were shown in the lobes in patients
with moderate (β = −0.981, p = 0.141) and severe emphy-
sema (β = −0.673, p = 0.318).
Discussion
This study assessed the association between pre-existing
BE and newly diagnosed lung cancer in terms of the
Table 1 Demographic Characteristics of the Study Population
Characteristics Patients with bronchiectasis and newly
diagnosed lung cancer (n = 81)
Age, years, median (IQR) 70 (61–76)
Male, n (%) 52 (64.2)







Presence and severity of
emphysema on CT, n (%)
No/mild emphysema 53 (65.4)
Moderate emphysema 20 (24.7)
Severe emphysema 8 (9.9)
Spirometry, mean ± SD
FEV1/FVC, ratio 67.7 ± 15.2
FEV1 predicted (%) 87.9 ± 23.4
FVC predicted (%) 91.1 ± 20.9
Charlson comorbidity
index, mean ± SD
1.4 ± 1.1
IQR interquartile range, SD standard deviation, CT computed tomography
Kim et al. BMC Pulmonary Medicine  (2016) 16:151 Page 3 of 6
lobar distribution. It revealed that the presence of pre-
existing BE was associated with a significantly lower risk
of lung cancer in the same lobe. These results are inter-
esting and suggest another aspect of the relationship be-
tween chronic inflammatory airway diseases and lung
cancer. In addition, our data also provide information
about the prevalent location of lung cancer and BE in
patients which the two diseases coexist. Compared to
lung cancer, which most commonly involved the right
upper lobe, BE most commonly involved the left lower
lobe. To our knowledge, this would be the first descrip-
tion of the association between BE and lung cancer by
location of the disease detected using CT at the level of
lung lobes [6, 17].
There is limited evidence for the pathophysiological
mechanism of the protective effect of BE in local car-
cinogenesis shown in our study. However, indirect bio-
logical plausibility exists. There are reports of elevated
serum TGF-β1 levels in patients with BE [5]. In normal
and premalignant cells, TGF-β enforces homeostasis and
tumor-suppressive effects by regulating cell-autonomous
cytostasis, differentiation, and apoptosis. In addition to
its direct inhibitory effects, TGF-β can restrict epithelial
cell proliferation and carcinogenesis by blocking the pro-
duction of paracrine factors in the stromal cells [8, 9].
Other plausibility includes the CTFR gene. A case–con-
trol study suggested that the ΔF508 deletion in the
CFTR gene in patients with cystic fibrosis, which shows
radiological features of BE, is an important protective
variant for lung cancer risk [10]. However, more re-
search is needed to identify a biological mechanism that
can clearly explain our findings.
Since previous studies report a positive association be-
tween the chronic inflammation in COPD or smoking
and the risk of squamous cell carcinoma, it is notable
that the majority of patients in our study were diagnosed
with adenocarcinoma [2, 18]. Moreover, among the pa-
tients diagnosed with lung cancer, 46 % were never-
smokers, and 65 % had no or mild emphysema. The high
proportion of adenocarcinoma, never-smokers, and non-
emphysematous subjects among the diagnosed lung can-
cer patients suggests that the majority of lung cancers in
patients with pre-existing BE occurs independently of
Table 2 Histologic Types and Staging of Lung Cancer
Characteristics Patients with bronchiectasis











37 (84.1) 36 (97.3)
Adenocarcinoma
17 (38.6) 25 (67.6)
Squamous cell
carcinoma




3 (6.8) 3 (8.1)
Others 3 (6.8) 4 (10.8)
Small cell lung
cancer





I 12 (27.3) 18 (48.6)
II 4 (9.1) 2 (5.4)
III 7 (15.9) 10 (27.0)






3 (6.8) 1 (2.7)
Extensive
disease
4 (9.1) 0 (0)
Table 3 Lobar Distribution and Characteristics of Lung Cancer
and Bronchiectasis
Characteristics Total 486 lobes in 81 patients
Affected lobes with lung cancer
RUL, n (%) 27 (5.6)
RML, n (%) 5 (1.0)
RLL, n (%) 20 (4.1)
LUL, n (%) 19 (3.9)
Lingula, n (%) 1 (0.2)
LLL, n (%) 13 (2.7)
Number of lobes affected
with BE per patients, mean ± SD
1.7 ± 0.8
Affected lobes with BE
RUL, n (%) 27 (5.6)
RML, n (%) 16 (3.3)
RLL, n (%) 26 (5.6)
LUL, n (%) 23 (4.7)
Lingula, n (%) 6 (1.2)
LLL, n (%) 36 (7.4)
BE severity index
(modified Bhalla system), mean ± SD
8.0 ± 5.9
BE severity index (Reiff score),
mean ± SD
4.4 ± 2.1
Lobes with combined BE
and lung cancer, n (%)
11 (2.3)
Lobes with BE only, n (%) 123 (25.3)
Lobes with lung cancer only, n (%) 74 (15.2)
BE bronchiectasis, SD standard deviation, RUL right upper lobe, RML right
middle lobe, RLL right lower lobe, LUL left upper lobe, LLL left lower lobe
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chronic inflammation. These findings can support our
theory that the chronic inflammation caused by BE is
not associated with an increased risk of lung cancer.
Previous epidemiological reports have aimed to evaluate
the association between prior lung diseases and the risk of
lung cancer. They showed that some chronic respiratory
diseases, including bronchitis and emphysema, are posi-
tively associated with the risk of lung cancer [17, 19].
However, these efforts focused mainly on evaluating dis-
eases and chronic inflammation associated with smoking,
a major contributor to lung cancer. To date, the mechan-
ism of airway inflammation in BE, and the association be-
tween BE and lung cancer remains unclear. Recently, a
nationwide cohort study from Taiwan reported that pa-
tients with underlying BE had a 2.36-fold increased risk of
lung cancer compared to patients without BE. However,
this study has limitations in confirming the disease status
only by the diagnosis codes provided from the registered
hospitals, and including only inpatients as subjects diag-
nosed with BE, who had significantly higher rate of co-
morbidities possibly related to cancer. Moreover, the
study used a database that did not contain information on
smoking status of the participants, which is a possible
strong confounding factor when evaluating risk of lung
cancer. The study also could not provide any information
about the severity or location of BE and the histological
type of lung cancer, which is important when discussing
the possible effects of BE and inflammation on the risk of
lung cancer [20]. Although our study included a relatively
small number of subjects, we were able to obtain detailed
information about the diagnosed BE and lung cancer for
each patient, and the data on the location of BE and lung
cancer made it possible to perform analyses within levels
of lung lobes. Results of our study are in concordance with
a recent case–control study from South Korea which re-
ported that the concomitant presence of BE was associ-
ated with a lower risk of lung cancer in COPD patients
[21]. Although BE is a representative chronic inflamma-
tory airway disease causing permanent dilatation of the
bronchi and is accompanied by high levels of
inflammatory cytokines, our results suggest that the
chronic inflammation caused by BE might produce differ-
ent cytokines compared with other airway diseases and
acts in a different way in carcinogenesis of the lung.
The main strength of our study is that the presence of
lung cancer and BE was assessed with chest CT, a pre-
cise means of evaluating the location of the disease at
the level of the lung lobes. In addition, because we ana-
lyzed the association between the two diseases by loca-
tion within patients known to have both diseases, the
possible confounding factors of the risk of lung cancer
in each patient (e.g., age, gender, and smoking status)
could be ignored in our study.
To interpret our results correctly, we should consider
the limitations of this study. First, given its retrospective
design, by selecting patients who were diagnosed with
lung cancer, there might have been selection bias enrol-
ling patients at higher risk of, or more susceptible to,
lung cancer. However, since the study design was pow-
ered to evaluate the association between BE and lung
cancer by the locations of the two diseases within each
subject, rather than an epidemiology study evaluating a
certain population, possible selection bias is not ex-
pected to have contributed to the significant results of
our study. Second, our data contains no detailed clinical
information on the history of BE (e.g. frequency of exac-
erbations, type of infection, length of follow up, and re-
ceived treatments), which can be an important issue
when discussing the role of chronic inflammation in BE.
Lastly, due to the limited data collected on the field of
inflammation and carcinogenesis related BE, the validity
of the potential explanations on our findings and the
role of chronic inflammation might be low. Nevertheless,
considering the limited data and difficulty to perform
large-scaled studies on the association between BE and
lung cancer, our results still would provide novel and
relevant information, and motivation for further studies.
Although this study was not a longitudinal study
following BE patients, it is reasonable to believe that
in the patients evaluated in our study, BE preceded
the development of lung cancer since BE is generally
accepted to be a chronic condition following infec-
tion in childhood, while lung cancer usually develops
within years of the initial diagnosis [22]. Moreover,
patients were excluded if they had BE secondary to
mechanical effects caused by lung cancer. Therefore,
despite the retrospective design, we insist that our
results represent a temporal relationship between BE
and lung cancer, rather than a coincidental finding.
Conclusions
Regionally, pre-existing BE was associated with a lower
risk of the occurrence of lung cancer in the same lobe.
Table 4 Risk of Lung Cancer in Patients with Underlying
Bronchiectasis Estimated by General Estimating Equationa
Population β-value 95 % CI p-value
Total −1.091 −1.716 - -0.466 0.001
Classified by smoking history
Current/Former smoker −1.012 −1.869 - -0.155 0.021
Never-smoker −1.152 −2.043 - -0.261 0.011
Classified by emphysema severity
No/mild emphysema −1.244 −2.075 - -0.412 0.003
Moderate emphysema −0.981 −2.287 - 0.325 0.141
Severe emphysema −0.673 −1.995 - 0.649 0.318
a β-value calculated by evaluating bronchiectasis as a risk factor of lung cancer
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Additional file
Additional file 1: Figure S1. Example CT images of (A) underlying
bronchiectasis and newly diagnosed lung cancer existing in the same
lobe and (B) secondary traction bronchiectasis caused by lung cancer.
(ZIP 7247 kb)
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